Relative proportions of serum carbamazepine and its pharmacologically active 10, 11-epoxy derivative: Effect of polytherapy and renal insufficiency

Upsala Journal of Medical Sciences

Volumn 113, Issue 2, 2008, Pages 171-180

  Tutor Crespo, María J ^a   Hermida, Jesús ^a   Tutor, J Carlos ^a  

^a Instituto de Salud Carlos III   (Spain)

Author keywords

Carbamazepine; Carbamazepine 10,11 epoxide; EMIT; HPLC; Renal insufficiency; Therapeutic monitoring

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD; CHEMISTRY; CHILD; DRUG MONITORING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY FAILURE; MALE; MIDDLE AGED; PRESCHOOL CHILD; ULTRAVIOLET SPECTROPHOTOMETRY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; CARBAMAZEPINE; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; RENAL INSUFFICIENCY; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 48949089547     PISSN: 03009734     EISSN: None     Source Type: Journal    
DOI: 10.3109/2000-1967-225     Document Type: Article

References (26)

1. Amore BM, Kalhorm TK, Skiles GL et al (1997) Characterization of carbamazepine metabolism in a mouse model of carbamazepine teratogeneity. Drug Metab Dispos ; 25: 953-62.
2. Maggs JL, Pirmohamed M, Kitteringham NR, Park BK (1997) Characterization of the metabolites of carbamazepine in patient urine by liquid chromatography/mass spectrometry. Drug Metab Dispos; 25: 275-80.
3. Reith DM, Appleton DB, Hooper W, Eadie MJ (2000) The effect of body size on the metabolic clearance of carbamazepine. Biopharm Drug Dispos; 21: 103-11.
4. Vree TB, Janssen TJ, Hekster YA, Termond EF, van de Dries Ac, Wijnands WJ (1986) Clinical pharmacokinetics of carbamzepine and its epoxy and hydroxy metabolites in humans after an overdose. Ther Drug Monit; 8: 297-304.
5. Potter JM, Donnelly A (1998) Carbamazepine-10,11-epoxyde in therapeutic monitoring. Ther Drug Monit; 20: 652-57.
6. Ramsay RE, McManus DQ, Guterman A et al (1990) Carbamazepine metabolism in humans: effect of concurrent anticonvulsant therapy. Ther Drug Monit; 12: 235-41.
7. Liu H, Delgado MR (1994) Improved therapeutic monitoring in epileptic children using carbamazepine polytherapy. Ther Drug Monit; 16: 132-38.
8. Warner A, Provitera M, Bates D (1988) Standards of laboratory practice: antiepileptic drug monitoring. Clin Chem; 44: 1085-95.
9. Frank EL, Schwarz EL, Juenke J, Annesley TM, Roberts WL (2002) Performance characteristics of four immunoassays for antiepileptic drugs on the Immulite 2000 automated analyser. Am J Clin Pathol; 118: 124-31.
10. Hermida J, Tutor JC (2003) How suitable are currently used carbamazepine immunoassays for quantifying carbamazepine-10,11-epoxide in serum samples?. Ther Drug Monit; 25: 384-88.
11. Shen S, Elin RJ, Soldin SJ (2001) Characterization of cross reactivity by carbamazepine-10,11-epoxide with carbamazepine assays. Clin Biochem; 34: 157-58.
12. Willimowska J, Gomollka E, Pasich A, Jenner B, Szpak D (2005) Comparison of fluorescence polarization immunoassay and high performance liquid chromatography for determination of carbamazepine concentration in blood of poisoned patients. Przegl Lek; 62: 595-98.
13. Hermida J, Bóveda MD, Vadillo FJ, Tutor JC (2002) Comparison between the Cobas Integra immunoassay and high-performance liquid chromatography for therapeutic monitoring of carbamazepine. Clin Biochem; 35: 251-24.
14. Parant F, Bossu H, Gagnieu MC, Lardet G, Moulsma M (2003) Cross-reactivity assessment of carbamazepine-10,11-epoxide, and 10-hydroxy-carbazepine in two automated carbamazepine immunoassys: PETINIA and EMIT 2000. Ther Drug Monit; 25: 41-45.
15. Lancelin F, Cattelotte J, Boyer C et al (2003) Influence de la carbamazépine-10,11-epoxide dans le dosage de la carbamazépine Dimension Flex® carbamazepine. Immunoanal Biol Spec; 18: 354-59.
16. Dade Behring Inc. Syva Emit® 2000 Carbamazepine Assay. Package insert (revised October 2004).
17. Méndez-Alvarez E, Soto-Otero R, Sierra-Marcuño G (1986) The effect of storage conditions on the stability of carbamazepine and carbamazepine-10,11-epoxide in plasma. Clin Chim Acta; 154: 243-46.
18. Van Tyle JH, Winter ME (2004) Carbamazepine. In: Winter ME, editor. Basic Clinical Pharmacokinetics. Fourth Edition. Philadelphia: Lippincot Willians & Wilkins: 172-82.
19. Hoek FJ, Kemperman FAW, Krediet RT (2003) A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transpl; 18: 2024-31.
20. Levey AS, Bosch JP, Lewis JB et al (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med; 130: 461-70.
21. Shah VP, Midha KK, Dighe S et al (1991) Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report. Eur J Drug Metab Pharmacokinet; 16: 249-55.
22. Shah VP, Midha KK, Findlay JWA et al (2000) Bioanalytical methods validation- A revisit with a decade of progress. Pharm Res; 17: 1551-57.
23. Abrahamson M, Olafsson I, Palsdottir A et al (1990) Structure and expression of the human cystatin C gene. Biochem J; 268: 287-94.
24. Pirttilä TJ, Manninen A, Jutila L et al (2005) Cystatin C expression is associated with granule cell dispersion in epilepsy. Ann Neurol; 58: 211-23.
25. Davies JA (1995) Mechanisms of action of antiepileptic drugs. Seizure; 4: 267-31.
26. Tutor-Crespo MJ, Hermida J, Tutor JC (2007) Phenytoin immunoassay measurements in serum samples from patients with renal insufficiency: comparison with high-performance liquid chromatography. J Clin Lab Anal; 21: 119-23.